Phase II
Shares of Bellerophon Therapeutics have plunged nearly 75 percent this morning after the company announced its Phase III pulmonary arterial hypertension failed to meet endpoints following a pre-specified interim analysis from a Data Monitoring Committee.
An investigational gene therapy treatment for hemophilia A has seen a 97 percent response rate after one treatment for the 12 trial participants, Spark Therapeutics announced this morning.
Ironwood Pharmaceuticals, located in Cambridge, Massachusetts, released its second-quarter financial report and updated its business activities. Key among the announcements was the termination of a license deal with AstraZeneca for its lesinurad franchise.
Ovid Therapeutics is shouting good news from the rooftops regarding its mid-stage Angelman Syndrome study, but investors are not convinced.
Now that July is over, the U.S. Food and Drug Administration (FDA) appears to be back in full swing with a full docket of drug decisions to make. There are four therapeutics with PDUFA dates this week involving six biopharma companies. Here’s a look.
Atlanta-based Celtaxsys reported results from its Phase II EMPIRE-CF clinical trial of acebilustat for cystic fibrosis (CF), putting a positive spin on what looks to be a failed clinical trial.
Cambridge, Massachusetts-based Epizyme emphasized its efforts to move tazemetostat back into clinical trials in its second-quarter financial report.
Oncorus, a biotechnology company based in Cambridge, Massachusetts, announced that Theodore (Ted) T. Ashburn had been chosen as the company’s new president and chief executive officer.
Chinese biotech company Ascletis Pharma debuted on the Hong Kong stock exchange, rising as much as 6.4 percent, but ending the day where it started.
ARCA Biopharma, located in Westminster, Colorado, announced mixed but positive outcomes from a Phase II clinical trial of its beta-blocker Gencaro for atrial fibrillation (AF) patients with heart failure (HF).
PRESS RELEASES